|
Synonyms: BMS-224818 | LEA29Y | Nulojix®
belatacept is an approved drug (FDA (2011), EMA (2011))
Compound class:
Peptide
Comment: A recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). CTLA-4 is essential for T-cell co-activation.
Belatecept differs from abatacept by only 2 amino acids. 
View more information in the IUPHAR Pharmacology Education Project: belatacept |
| Immunopharmacology Comments |
| Approved for prophylaxis of organ rejection after kidney transplant. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Allograft rejection | Approved drug for the prophylaxis of organ rejection after kidney transplant in EBV-exposed patients. | ||
